A Phase 3 interventional study of Tirzepatide and Placebo in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 53 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-20.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment, is one of 8 that started in 2019, is one of 17 in phase 3, and was the 10th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:
Las Rías Medical Center · Sites in Paraguay
Ages 18–70
Stanford University · Sites in United States
Ages 30–70 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–75
Matthew J. Budoff · Sites in United States
Ages 40–80
Dr Adnan Agha · Sites in United Arab Emirates
Ages 18–99
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 6 · Phase 3 17 · Phase 4 10
First in 2016; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 478 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 160 across the 43 interventional studies. Of the 29 that completed or were terminated, 25 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 43 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 59th largest by enrollment of the 232 interventional ones that give a count, is one of 12 that started in 2019, is one of 85 in phase 3, and was the 150th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
3 of the studies testing tirzepatide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07299084Eli Lilly and CompanyA Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | 2026-11 |
| NCT07438444Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | 2027-07 |
| NCT07588438Las Rías Medical CenterEfficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. | 2027-08-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone. The study will last approximately 47 weeks and may include about 15 visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 5 milligrams (mg) of tirzepatide as subcutaneous injection once a week.
Drug: Tirzepatide
Participants received 10mg of tirzepatide as subcutaneous injection once a week.
Drug: Tirzepatide
Participants received 15mg of tirzepatide as subcutaneous injection once a week.
Drug: Tirzepatide
Participants received placebo as subcutaneous injection once a week.
Drug: Placebo
Administered SC
Also known as: LY3298176
Administered SC
Change From Baseline in Hemoglobin A1c (HbA1c)
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Prior Use of oral antihyperglycemic medication (OAM) (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 40
Change From Baseline in Body Weight
Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Prior Use of OAM (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 40
Percentage of Participants With HbA1c Target Value of <7%
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
Time frame: Week 40
Change From Baseline in Fasting Serum Glucose
Fasting serum glucose (FSG) is a test to determine sugar levels in serum sample after an overnight fast. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Prior Use of OAM (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 40
Percentage of Participants With HbA1c Target Value of <5.7%
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
Time frame: Week 40
Mean Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values
The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Postmeal, Midday Premeal, Midday 2-hour Postmeal, Evening Premeal, Evening 2-hour Postmeal and Bedtime. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Prior Use of OAM (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 40
Percentage of Participants Who Achieved Weight Loss ≥5%
Percentage of Participants who Achieved Weight Loss ≥5%.
Time frame: Week 40
Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 Millimole/Liter (mmol/L)] or Severe Hypoglycemia
The hypoglycemia events were defined by participant reported events with blood glucose \<54mg/dL) (\<3.0 mmol/L\] or severe hypoglycemia. Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. The rate of postbaseline hypoglycemia was estimated by negative binomial model: number of episodes = Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Prior Use of OAM (Yes, No) + Treatment, with log (exposure in days/365.25) as an offset variable.
Time frame: Baseline through end of safety follow-up (up to week 44)
Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide
Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide. AUC is a combined measure obtained from Week 7, 15 and 23, and a single averaged measure of AUC was reported.
Time frame: Week 7, 15 and 23
| Milestone | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| Started | 121 | 121 | 121 | 115 |
| Received at least one dose of study drug | 121 | 121 | 121 | 115 |
| Completed | 114 | 112 | 103 | 99 |
| Not completed | 7 | 9 | 18 | 16 |
| Withdrew: Adverse event | 1 | 3 | 1 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 | 2 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 3 | 13 | 6 |
| Withdrew: Participant left the country | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 2 | 3 | 5 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Prior Use of oral antihyperglycemic medication (OAM) (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).
| Percentage of HbA1c | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) | -1.87 ± 0.094 | -1.89 ± 0.096 | -2.07 ± 0.098 | 0.04 ± 0.105 |
Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Prior Use of OAM (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).
| Kilograms (kg) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| Change From Baseline in Body Weight | -7.0 ± 0.52 | -7.8 ± 0.53 | -9.5 ± 0.54 | -0.7 ± 0.57 |
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
| Percentage of participants | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| Percentage of Participants With HbA1c Target Value of <7% | 86.78 | 91.53 | 87.93 | 19.64 |
Fasting serum glucose (FSG) is a test to determine sugar levels in serum sample after an overnight fast. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Prior Use of OAM (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).
| milligram per Deciliter (mg/dL) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| Change From Baseline in Fasting Serum Glucose | -43.6 ± 3.40 | -45.9 ± 3.45 | -49.3 ± 3.62 | 12.9 ± 4.00 |
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
| Percentage of participants | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| Percentage of Participants With HbA1c Target Value of <5.7% | 33.88 | 30.51 | 51.72 | 0.89 |
The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Postmeal, Midday Premeal, Midday 2-hour Postmeal, Evening Premeal, Evening 2-hour Postmeal and Bedtime. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Prior Use of OAM (Yes, No) + Treatment + Time + Treatment\*Time (Type III sum of squares).
| mg/dL | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| Morning Premeal - Fasting | -46.9 ± 2.09 | -47.9 ± 2.11 | -45.7 ± 2.23 | -9.2 ± 2.53 |
| Morning 2-hour Postmeal | -69.5 ± 3.41 | -61.4 ± 3.44 | -68.9 ± 3.66 | -11.6 ± 4.12 |
| Midday Premeal | -43.5 ± 2.80 | -42.5 ± 2.82 | -42.7 ± 3.00 | -2.6 ± 3.42 |
| Midday 2-hour Postmeal | -64.2 ± 3.60 | -60.0 ± 3.63 | -63.4 ± 3.84 | -12.7 ± 4.33 |
| Evening Premeal | -44.8 ± 2.80 | -45.1 ± 2.82 | -42.3 ± 3.02 | -5.8 ± 3.38 |
| Evening 2-hour Postmeal | -61.9 ± 3.76 | -62.8 ± 3.81 | -63.5 ± 4.03 | -10.3 ± 4.52 |
| Bedtime | -57.0 ± 3.49 | -59.8 ± 3.52 | -60.8 ± 3.66 | -9.1 ± 4.10 |
Percentage of Participants who Achieved Weight Loss ≥5%.
| Percentage of participants | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| Percentage of Participants Who Achieved Weight Loss ≥5% | 66.94 | 77.97 | 76.72 | 14.29 |
The hypoglycemia events were defined by participant reported events with blood glucose \<54mg/dL) (\<3.0 mmol/L\] or severe hypoglycemia. Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. The rate of postbaseline hypoglycemia was estimated by negative binomial model: number of episodes = Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Prior Use of OAM (Yes, No) + Treatment, with log (exposure in days/365.25) as an offset variable.
| Episodes/participant/365.25 days | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 Millimole/Liter (mmol/L)] or Severe Hypoglycemia | 0.02 ± 0.002 | 0.02 ± 0.002 | 0.02 ± 0.002 | 0.04 ± 0.028 |
Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide. AUC is a combined measure obtained from Week 7, 15 and 23, and a single averaged measure of AUC was reported.
| nanograms*hours per milliliter (h*ng/mL) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide |
|---|---|---|---|
| Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide | 86900 ± 25.4 | 171000 ± 26.2 | 252000 ± 23.3 |
Collected over Baseline to end of Safety follow-up (up to 44 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 5 mg Tirzepatide | 0/121 (0%) | 5/121 (4.1%) | 50/121 (41.3%) |
| 10 mg Tirzepatide | 0/121 (0%) | 2/121 (1.7%) | 55/121 (45.5%) |
| 15 mg Tirzepatide | 0/121 (0%) | 1/121 (0.8%) | 53/121 (43.8%) |
| Placebo | 1/115 (0.9%) | 3/115 (2.6%) | 54/115 (47%) |
| Event | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/121 | 0/121 | 0/121 | 1/115 |
| Cardiac failureCardiac disorders | 0/121 | 0/121 | 0/121 | 1/115 |
| CholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/121 | 0/121 | 0/121 | 1/115 |
| Supraventricular tachycardiaCardiac disorders | 1/121 | 0/121 | 0/121 | 0/115 |
| Colitis ischaemicGastrointestinal disorders | 1/121 | 0/121 | 0/121 | 0/115 |
| Clostridium difficile infectionInfections and infestations | 0/121 | 1/121 | 0/121 | 0/115 |
| PneumoniaInfections and infestations | 0/121 | 1/121 | 0/121 | 0/115 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/121 | 0/121 | 1/121 | 0/115 |
| AdenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/121 | 0/121 | 0/121 | 0/115 |
| SyncopeNervous system disorders | 1/121 | 0/121 | 0/121 | 0/115 |
| Event | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|---|
| HyperglycaemiaMetabolism and nutrition disorders | 4/121 | 5/121 | 3/121 | 31/115 |
| NauseaGastrointestinal disorders | 14/121 | 16/121 | 22/121 | 7/115 |
| DiarrhoeaGastrointestinal disorders | 14/121 | 17/121 | 14/121 | 9/115 |
| DyspepsiaGastrointestinal disorders | 11/121 | 8/121 | 7/121 | 4/115 |
| NasopharyngitisInfections and infestations | 7/121 | 8/121 | 8/121 | 10/115 |
| Decreased appetiteMetabolism and nutrition disorders | 5/121 | 8/121 | 10/121 | 1/115 |
| HeadacheNervous system disorders | 5/121 | 4/121 | 5/121 | 9/115 |
| ConstipationGastrointestinal disorders | 7/121 | 6/121 | 8/121 | 1/115 |
| VomitingGastrointestinal disorders | 4/121 | 3/121 | 7/121 | 2/115 |
| InfluenzaInfections and infestations | 7/121 | 3/121 | 0/121 | 2/115 |
All randomized participants.
| Age, Continuous(years) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 54.10 ± 11.88 | 55.80 ± 10.35 | 52.90 ± 12.34 | 53.60 ± 12.79 | 54.10 ± 11.88 |
| Sex: Female, Male(Participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|---|
| Female | 65 | 49 | 58 | 59 | 231 |
| Male | 56 | 72 | 63 | 56 | 247 |
| Ethnicity (NIH/OMB)(Participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 50 | 54 | 55 | 48 | 207 |
| Not Hispanic or Latino | 48 | 49 | 42 | 45 | 184 |
| Unknown or Not Reported | 23 | 18 | 24 | 22 | 87 |
| Race (NIH/OMB)(Participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 31 | 31 | 30 | 26 | 118 |
| Asian | 45 | 43 | 42 | 38 | 168 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 4 | 6 | 5 | 22 |
| White | 38 | 43 | 43 | 46 | 170 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|---|
| India | 18 | 20 | 18 | 17 | 73 |
| Japan | 23 | 22 | 23 | 21 | 89 |
| Mexico | 42 | 40 | 42 | 40 | 164 |
| Puerto Rico | 2 | 4 | 5 | 1 | 12 |
| United States | 36 | 35 | 33 | 36 | 140 |
| Hemoglobin A1c(Percentage of HbA1c) | 5 mg Tirzepatide | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 7.97 ± 0.841 | 7.90 ± 0.78 | 7.85 ± 1.02 | 8.05 ± 0.80 | 7.94 ± 0.87 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Jun 2019 to primary completion in Oct 2020, 16 months.
Results were first posted in Oct 2021, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 16 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide